X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1327) 1327
Publication (116) 116
Newsletter (30) 30
Book Review (19) 19
Book Chapter (6) 6
Dissertation (2) 2
Conference Proceeding (1) 1
Magazine Article (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
rosuvastatin (960) 960
humans (869) 869
index medicus (829) 829
male (624) 624
statins (548) 548
rosuvastatin calcium (518) 518
female (484) 484
pharmacology & pharmacy (459) 459
middle aged (391) 391
atorvastatin (364) 364
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (351) 351
aged (307) 307
cholesterol (274) 274
simvastatin (270) 270
animals (248) 248
adult (242) 242
cardiac & cardiovascular systems (231) 231
drug interactions (229) 229
fluorobenzenes - therapeutic use (225) 225
pharmacokinetics (221) 221
pyrimidines - therapeutic use (211) 211
sulfonamides - therapeutic use (210) 210
pravastatin (193) 193
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology (191) 191
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (188) 188
antilipemic agents (185) 185
analysis (173) 173
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (170) 170
treatment outcome (170) 170
research (160) 160
risk factors (159) 159
fluorobenzenes - pharmacology (155) 155
risk (147) 147
sulfonamides - pharmacology (147) 147
drug therapy (145) 145
pyrimidines - pharmacology (145) 145
therapy (143) 143
lipids (141) 141
cholesterol, ldl - blood (135) 135
atherosclerosis (133) 133
cardiovascular disease (128) 128
safety (126) 126
dosage and administration (124) 124
hydroxymethylglutaryl-coa reductase inhibitors - pharmacokinetics (124) 124
prevention (124) 124
dose-response relationship, drug (123) 123
abridged index medicus (115) 115
hypercholesterolemia (115) 115
cardiovascular (113) 113
statin (113) 113
c-reactive protein (109) 109
fluorobenzenes - administration & dosage (109) 109
mortality (108) 108
care and treatment (107) 107
double-blind method (107) 107
rats (107) 107
fluorobenzenes - adverse effects (105) 105
cardiovascular-disease (103) 103
inflammation (103) 103
cardiovascular diseases (102) 102
health aspects (102) 102
pyrimidines - administration & dosage (102) 102
pyrimidines - adverse effects (101) 101
sulfonamides - adverse effects (101) 101
coronary-heart-disease (100) 100
hypercholesterolemia - drug therapy (100) 100
medicine, general & internal (100) 100
fluorobenzenes - pharmacokinetics (99) 99
sulfonamides - administration & dosage (99) 99
atorvastatin calcium (98) 98
drug therapy, combination (96) 96
efficacy (96) 96
pyrimidines - pharmacokinetics (93) 93
sulfonamides - pharmacokinetics (90) 90
young adult (89) 89
cardiovascular agents (87) 87
disease (87) 87
low density lipoproteins (87) 87
internal medicine (85) 85
medicine & public health (85) 85
cardiology (84) 84
statin therapy (84) 84
nutritional and metabolic diseases (83) 83
pharmacology (83) 83
diabetes (82) 82
heart failure (80) 80
aged, 80 and over (79) 79
studies (79) 79
density-lipoprotein cholesterol (76) 76
clinical trials (74) 74
ezetimibe (74) 74
metaanalysis (72) 72
peripheral vascular disease (72) 72
rosuvastatin calcium - administration & dosage (72) 72
cardiovascular diseases - prevention & control (71) 71
rosuvastatin calcium - therapeutic use (71) 71
anticholesteremic agents - therapeutic use (70) 70
primary prevention (70) 70
prospective studies (70) 70
dyslipidemia (68) 68
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1349) 1349
Spanish (4) 4
Russian (3) 3
Chinese (2) 2
Dutch (2) 2
Czech (1) 1
French (1) 1
German (1) 1
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 09/2018, Volume 84, Issue 9, pp. 1941 - 1949
Aims Previous pharmacokinetic characterization of a transporter probe cocktail containing digoxin (P‐gp), furosemide (OAT1, OAT3), metformin (OCT2, MATE1,... 
drug transporters | pharmacokinetics | drug interactions | Phase I | METFORMIN | IMPORTANT DETERMINANTS | VOLUNTEERS | FUROSEMIDE | PHARMACOLOGY & PHARMACY | ROSUVASTATIN | Complications and side effects | Medical tests | Drug interactions | Furosemide | Original
Journal Article
Journal Article
Pharmaceutical Research, ISSN 0724-8741, 2/2012, Volume 29, Issue 2, pp. 411 - 426
To establish in vitro and in silico models that predict clinical drug–drug interactions (DDIs) with the OATP1B1 (SLCO1B1) transporter.The inhibitory effect of... 
Biomedical Engineering | Biochemistry, general | Biomedicine | MRP2 | Pharmacy | Medical Law | inhibition | in silico | Pharmacology/Toxicology | in vitro – in vivo extrapolation | OATP1B1 | In silico | Inhibition | In vitro-in vivo extrapolation | HEPATIC-UPTAKE | IDENTIFICATION | CHEMISTRY, MULTIDISCIPLINARY | ATORVASTATIN | ANION TRANSPORTING POLYPEPTIDE | CYCLOSPORINE-A | PHARMACOKINETICS | in vitro-in vivo extrapolation | PLASMA-CONCENTRATIONS | LIVER | PHARMACOLOGY & PHARMACY | EXPRESSION | ROSUVASTATIN | Estradiol - analogs & derivatives | Gene Expression | Organic Anion Transporters - antagonists & inhibitors | Humans | Organic Anion Transporters - metabolism | Atorvastatin Calcium | Pyrroles - pharmacology | Drug Interactions | Models, Biological | Computer Simulation | HEK293 Cells | Solute Carrier Organic Anion Transporter Family Member 1b1 | Estradiol - pharmacology | Heptanoic Acids - pharmacology | Complications and side effects | Antiviral agents | Cyclosporine | Gemfibrozil | Drug interactions | Fibric acids | Clinical trials | Models | Inhibitor drugs | in vitro–in vivo extrapolation | Research Paper | Pharmaceutical Sciences | Basic Medicine | PHARMACY | Galenisk farmaci | Pharmaceutics | Medical and Health Sciences | Medicin och hälsovetenskap | Farmaceutiska vetenskaper | Biopharmaceutics | Medicinska och farmaceutiska grundvetenskaper | Biopharmacy | FARMACI | Biofarmaci
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 06/2019, Volume 105, Issue 6, pp. 1345 - 1361
Many drug–drug interactions (DDIs) are based on alterations of the plasma concentrations of a victim drug due to another drug causing inhibition and/or... 
MARKEDLY DECREASES | CYTOCHROME-P450 | INHIBITION | TIME-DEPENDENT PHARMACOKINETICS | PLASMA-CONCENTRATIONS | GRAPEFRUIT JUICE | PHARMACOLOGY & PHARMACY | ROSUVASTATIN PHARMACOKINETICS | ENDOGENOUS BIOMARKERS | GENEVA COCKTAIL | INTERACTION ASSESSMENTS | State of the Art | Reviews
Journal Article
Journal Article
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 04/2017, Volume 101, Issue 4, pp. 519 - 530
Journal Article